Krish Patel, MD
@krishpatelmd.bsky.social
Director, Lymphoma Research @ Sarah Cannon Research Institute. Dad x 2. Duke Blue Devil x 4. Foodie. #lymsm #cll #CellTherapy. Views my own, not those of my institution.
Providing access to highly effective therapies in the communities where patients live is critical to improving outcomes. Safety of bsabs and CAR-T is continuously improving and we need partnerships to bring these therapies to more community oncology centers. #HemOnc #lymsm #MedSky
🎥 At #iwCART25, @krishpatelmd.bsky.social, Tara Graff, & Caron Jacobson shared their perspectives on how to improve access & delivery of T-cell engaging therapies (CAR-T and bispecifics) in the community.
Watch the discussion here:
👉 buff.ly/4s5IV1D
#HemOnc #CARTCell #ImmunoOnc #MedSky
Watch the discussion here:
👉 buff.ly/4s5IV1D
#HemOnc #CARTCell #ImmunoOnc #MedSky
June 3, 2025 at 10:53 PM
Reposted by Krish Patel, MD
SCRI expert, Dr. Stephen Strickland presented interim results for SENTI-202 at #AACR2025. This CAR NK cell therapy shows potential in treating relapsed AML, with several patients achieving complete remission. Read more www.usnews.com/news/health-...
#CancerResearch #CAR_NK_Therapy #AML #USNews
#CancerResearch #CAR_NK_Therapy #AML #USNews
May 2, 2025 at 6:55 PM
SCRI expert, Dr. Stephen Strickland presented interim results for SENTI-202 at #AACR2025. This CAR NK cell therapy shows potential in treating relapsed AML, with several patients achieving complete remission. Read more www.usnews.com/news/health-...
#CancerResearch #CAR_NK_Therapy #AML #USNews
#CancerResearch #CAR_NK_Therapy #AML #USNews
Reposted by Krish Patel, MD
This is so incredibly sad for cancer and specifically cell and gene therapy. I am profoundly grateful to Peter for his service, collaboration and dedication through an incredibly impactful career. CAR-T therapies would not be where they are without his efforts. www.wsj.com/politics/top...
March 29, 2025 at 1:14 AM
This is so incredibly sad for cancer and specifically cell and gene therapy. I am profoundly grateful to Peter for his service, collaboration and dedication through an incredibly impactful career. CAR-T therapies would not be where they are without his efforts. www.wsj.com/politics/top...
Reposted by Krish Patel, MD
We owe him much for his leadership at CBER during a period of remarkable therapeutic advances. The havoc caused by this administration will have a devastating impact for years.
www.washingtonpost.com/politics/202...
www.washingtonpost.com/politics/202...
RFK Jr. forces out Peter Marks, FDA’s top vaccine scientist
Marks, an architect of Operation Warp Speed for coronavirus vaccines, warned that a measles outbreak shows how confidence in science is being “undermined.”
www.washingtonpost.com
March 29, 2025 at 1:53 AM
We owe him much for his leadership at CBER during a period of remarkable therapeutic advances. The havoc caused by this administration will have a devastating impact for years.
www.washingtonpost.com/politics/202...
www.washingtonpost.com/politics/202...
So many exciting developments in MCL in the past few years. Much more to come also with a lot of exciting clinical trials and investigational therapies being developed. #lymsm #HemeSky
Hear the updates in #MantleCellLymphoma from #ASH24 and key takeaways for community oncologists in our wonderful interview with @krishpatelmd.bsky.social of @scrinetwork.bsky.social!
Click here to watch:
👉 buff.ly/4jmisjj 👈
#LYMsm #CTSM #HemOnc #HemeSky @ash.hematology.org
Click here to watch:
👉 buff.ly/4jmisjj 👈
#LYMsm #CTSM #HemOnc #HemeSky @ash.hematology.org
January 22, 2025 at 2:14 PM
Long awaited…Excited to see our multi-center effort of CD19 allo iPSC CAR-NK in B-cell #lymsm! Impt proof of concept:
-very low CRS ✅
-no ICANS ✅
-multi dose off shelf tx ✅
-durable responses in challenging histologies ✅
Lots still to do for the field of CAR-NK www.thelancet.com/journals/lan...
-very low CRS ✅
-no ICANS ✅
-multi dose off shelf tx ✅
-durable responses in challenging histologies ✅
Lots still to do for the field of CAR-NK www.thelancet.com/journals/lan...
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
FT596 was well tolerated as monotherapy or with rituximab and induced deep and durable responses in patients with indolent and aggressive lymphomas and the RP2D was preliminarily identified to be 1·8 × 109 cells for three doses per cycle. This study supports that cell therapy using iPSC-derived, gene-modified NK cells is a potent platform for cancer treatment and suggests that such a platform might address limitations of currently available immune cell therapies, including manufacturing time, heterogeneity, access, and cost.
www.thelancet.com
January 10, 2025 at 7:43 PM
Long awaited…Excited to see our multi-center effort of CD19 allo iPSC CAR-NK in B-cell #lymsm! Impt proof of concept:
-very low CRS ✅
-no ICANS ✅
-multi dose off shelf tx ✅
-durable responses in challenging histologies ✅
Lots still to do for the field of CAR-NK www.thelancet.com/journals/lan...
-very low CRS ✅
-no ICANS ✅
-multi dose off shelf tx ✅
-durable responses in challenging histologies ✅
Lots still to do for the field of CAR-NK www.thelancet.com/journals/lan...
Amazing and very important work for the field. 👏🏽👏🏽👏🏽
Happy to share our work published in Nature Medicine!
We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...
We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...
T cell malignancies after CAR T cell therapy in the DESCAR-T registry - Nature Medicine
This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France between 2018 and 2024 shows th...
www.nature.com
January 8, 2025 at 6:28 PM
Amazing and very important work for the field. 👏🏽👏🏽👏🏽
Every year this is how I feel after ASH. A final #ASHaiku
Every year it comes
ASH conference lights the path
Purpose renewed
#ASH24 #hematology #HemeSky #lymsm
Every year it comes
ASH conference lights the path
Purpose renewed
#ASH24 #hematology #HemeSky #lymsm
Are you feeling revitalized? 🎇
#ASH24 has been an incredible reminder of why we do what we do. The knowledge and inspiration gained here will undoubtedly lead to exciting advances as we return home to apply what we've learned.
Here's to a fantastic final day in San Diego!☀️ #HemeSky #Hematology
#ASH24 has been an incredible reminder of why we do what we do. The knowledge and inspiration gained here will undoubtedly lead to exciting advances as we return home to apply what we've learned.
Here's to a fantastic final day in San Diego!☀️ #HemeSky #Hematology
December 10, 2024 at 9:11 PM
Every year this is how I feel after ASH. A final #ASHaiku
Every year it comes
ASH conference lights the path
Purpose renewed
#ASH24 #hematology #HemeSky #lymsm
Every year it comes
ASH conference lights the path
Purpose renewed
#ASH24 #hematology #HemeSky #lymsm
Excited to be at ASH in my new role at SCRI! Stop by our booth to learn about exciting things happening in our network! #ASH24 #lymsm #CancerResearch
Join Sarah Cannon Research Institute and Sarah Cannon Cancer Network at #ASH24 Booth #1154 for "Meet the Expert" Sessions! Connect with top oncologists and explore cancer research innovations. #Oncology #CancerResearch @krishpatelmd.bsky.social @miketees.bsky.social
December 7, 2024 at 9:49 PM
Excited to be at ASH in my new role at SCRI! Stop by our booth to learn about exciting things happening in our network! #ASH24 #lymsm #CancerResearch
Reposted by Krish Patel, MD
Want to hear about the targeting of BTK for the treatment of CLL and NHL?
Then don't forget to watch our fantastic roundtable discussion with experts Tanya Siddiqi, Krish Patel & Alexey Danilov!
Click here:
👉https://buff.ly/4f3mR7s👈
#iwNHL24 #LYMsm #CLLsm #NonHodgkinLymphoma
Then don't forget to watch our fantastic roundtable discussion with experts Tanya Siddiqi, Krish Patel & Alexey Danilov!
Click here:
👉https://buff.ly/4f3mR7s👈
#iwNHL24 #LYMsm #CLLsm #NonHodgkinLymphoma
Targeting BTK to treat CLL and NHL: insights from BTKis and novel BTK degraders | VJHemOnc
In this video, Tanya Siddiqi, MD, City of Hope, Duarte, CA, Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, and...
buff.ly
December 7, 2024 at 11:00 AM
Want to hear about the targeting of BTK for the treatment of CLL and NHL?
Then don't forget to watch our fantastic roundtable discussion with experts Tanya Siddiqi, Krish Patel & Alexey Danilov!
Click here:
👉https://buff.ly/4f3mR7s👈
#iwNHL24 #LYMsm #CLLsm #NonHodgkinLymphoma
Then don't forget to watch our fantastic roundtable discussion with experts Tanya Siddiqi, Krish Patel & Alexey Danilov!
Click here:
👉https://buff.ly/4f3mR7s👈
#iwNHL24 #LYMsm #CLLsm #NonHodgkinLymphoma
On the way to @ash-hematology.bsky.social 2024. Beautiful middle TN sunrise over Cumberland River. Excited for science, collaboration, and all the best of #hematology #hemesky #lymsm #lymsky #ASH2024
December 5, 2024 at 12:53 PM
On the way to @ash-hematology.bsky.social 2024. Beautiful middle TN sunrise over Cumberland River. Excited for science, collaboration, and all the best of #hematology #hemesky #lymsm #lymsky #ASH2024
Reposted by Krish Patel, MD
A very exciting time to join Sarah Cannon. Cutting edge research in rapidly growing programs.
We are hiring to add to our 60+ leukemia/cell therapy/BMT physicians across the Sarah Cannon Transplant and Cellular Therapy Network - happy to connect at #ASH24 and share more about opportunities for clinical investigators and clinicians (pls direct message me 🙏)
December 4, 2024 at 9:37 PM
A very exciting time to join Sarah Cannon. Cutting edge research in rapidly growing programs.
Looking forward to full study presentation. I like the approach but devil is in the details. Followup is short and mPFS 16 mths R2 control arm not quite performing like AUGMENT (where R2 median pfs 27.6mths at 5yr f/u) but it is a randomized comparison. Are pts higher risk in this study 🤔?
#lymsm
#lymsm
#ASH24 LBA-1
Tafa+Len+R for r/r FL
N=548, med fu 14m
⬆️⬆️ in PFS w Tafa (22.4m vs 13.9m; HR 0.43)👏🏾👏🏾
Consistent benefit in all subgrps including POD24 (32% of study)!!,
CR 49.4% vs 39.8%
ORR 83.5% vs 72.4%
Med DOR 21.2m vs 13.6m
Med TTNT NR vs 28.8m #lymsm ash.confex.com/ash/2024/web...
Tafa+Len+R for r/r FL
N=548, med fu 14m
⬆️⬆️ in PFS w Tafa (22.4m vs 13.9m; HR 0.43)👏🏾👏🏾
Consistent benefit in all subgrps including POD24 (32% of study)!!,
CR 49.4% vs 39.8%
ORR 83.5% vs 72.4%
Med DOR 21.2m vs 13.6m
Med TTNT NR vs 28.8m #lymsm ash.confex.com/ash/2024/web...
Paper: Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
ash.confex.com
November 25, 2024 at 8:23 PM
Looking forward to full study presentation. I like the approach but devil is in the details. Followup is short and mPFS 16 mths R2 control arm not quite performing like AUGMENT (where R2 median pfs 27.6mths at 5yr f/u) but it is a randomized comparison. Are pts higher risk in this study 🤔?
#lymsm
#lymsm
Glofi-PolaRCHP 95/97% pfs/os 👀🤯
Ph2 glofi-RCHOP v glofi-polaRCHP 1L LBCL @mike_dickinson1
- 80 pts, 38% non-GC, 11% DHL
- CR: 70% RCHOP, 80% pola
- 1-yr PFS/OS: 88/96% R-CHOP, 95/97% pola
- no G3-5 CRS, no ICANS
- EOT PRs did not progress or converted to CR (cfDNA neg!)
Rethink EOT PET with BsAbs? #lymsm
- 80 pts, 38% non-GC, 11% DHL
- CR: 70% RCHOP, 80% pola
- 1-yr PFS/OS: 88/96% R-CHOP, 95/97% pola
- no G3-5 CRS, no ICANS
- EOT PRs did not progress or converted to CR (cfDNA neg!)
Rethink EOT PET with BsAbs? #lymsm
November 20, 2024 at 5:05 AM
Glofi-PolaRCHP 95/97% pfs/os 👀🤯